Pharmaceuticals

Global Denosumab Market 2025–2029: Competitive Insights and Opportunities

November 10, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Global Market Value Of The Denosumab Industry In 2025?

The denosumab market size has seen substantial growth in recent years. It is expected to expand from $3.27 billion in 2024 to $3.67 billion in 2025, at a compound annual growth rate (CAGR) of 12.1%. This historic growth can be attributed to various factors such as advancements in clinical trials and research, FDA approvals and key regulatory achievements, increasing public awareness of bone health, and successful strategic partnerships and marketing campaigns.

The denosumab market is poised for substantial expansion in the upcoming years. It is projected to attain a size of $5.48 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 10.6%. This anticipated growth is primarily driven by factors such as the increasing incidence of bone metastases, continuous advancements in cancer therapies, the widespread prevalence of osteoporosis, enhanced awareness concerning osteoporosis, and the securing of regulatory approvals for novel indications. Furthermore, major trends characterizing this forecast period include the formation of strategic collaborations and partnerships, the integration of digital health solutions, the broadening of indications and clinical applications, and ongoing progress in biosimilar development.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13835&type=smp

What Are The Key Drivers Of Growth In The Denosumab Market?

The rising occurrence of osteoporosis is anticipated to drive the expansion of the denosumab market in the future. This medical condition, osteoporosis, involves a weakening of bones, leading to reduced bone density and an elevated risk of fractures. Denosumab functions as a treatment for osteoporosis by inhibiting bone resorption through its action on the RANK ligand. For example, in September 2023, the National Center for Biotechnology Information, a US government agency, reported findings from the Canadian Longitudinal Study on Aging, indicating that among community-dwelling older adult females, physician-diagnosed osteoporosis had a prevalence of 12.7%, while DXA-confirmed osteoporosis was 5.9%. Furthermore, a cross-sectional study conducted by Buttros and colleagues identified a 24.6% prevalence of osteoporosis among postmenopausal women aged 40 to 75, determined through bone mineral density (BMD) measurements. Consequently, the growing incidence of osteoporosis is fueling the expansion of the denosumab market.

What Are The Different Segment Classifications Within The Denosumab Market?

The denosumab market covered in this report is segmented –

1) By Drug Classification: Prolia, Xgeva, Others

2) By Type: 60 mg, 120 mg

3) By End-Users: Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers

What Key Innovation Trends Are Fueling Advancements In The Denosumab Market?

Leading companies operating in the denosumab market are increasingly concentrating on introducing innovative solutions, such as first-line treatments for osteoporosis, to gain a competitive advantage. First-line treatment for osteoporosis denotes the initial or primary therapeutic strategy recommended by healthcare professionals for individuals diagnosed with the condition. For instance, in November 2022, Boan Biotech, a China-based biotechnology firm, obtained approval from China’s National Medical Products Administration (NMPA) for its denosumab biosimilar, Boyoubei, establishing it as the first Chinese company to develop a denosumab injection. It is also being developed for markets outside of China, including Europe and the United States, with intentions for global marketing. The drug has been endorsed as a first-line treatment for osteoporosis in numerous treatment guidelines. This medication possesses the capability to substantially reduce the risk of hip, non-vertebral, and vertebral fractures within this patient population. Additionally, Boyoubei is the first biosimilar to Prolia (the originator of denosumab) to be approved for marketing worldwide.

Which Major Industry Participants Are Leading The Denosumab Market Growth?

Major companies operating in the denosumab market report are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Novartis International AG, Sanofi SA, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Asahi Kasei Corporation, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company, Limited, Mylan N.V., Sandoz International GmbH, Daiichi Sankyo Company Limited, Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals PLC, Celltrion Inc., Amneal Pharmaceuticals Inc, Cadila Healthcare Limited, Lupin Limited, Biocon Limited, Torrent Pharmaceuticals Ltd., Jubilant Life Sciences Limited, Ajanta Pharma Limited

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/denosumab-global-market-report

Which Region Is Projected To Lead The Denosumab Market During The Forecast Period?

North America was the largest region in the denosumab market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the denosumab market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Denosumab Market Report:

https://www.thebusinessresearchcompany.com/customise?id=13835&type=smp

Browse Through More Reports Similar to the Global Denosumab Market 2025, By The Business Research Company

Anemia And Other Blood Disorder Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/anemia-and-other-blood-disorder-drugs-global-market-report

Antifungals Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/antifungals-global-market-report

Antiglaucoma Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/antiglaucoma-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795